A Wrap for 2010 !

[Guest guest]

As 2010 ends, we are encouraged by the amount of extraordinary research that has

been completed for Charcot Marie Tooth neuromuscular disease this year. We saw

the refreshingly positive resurrection of NT-3 as a nerve growth factor,

followed by initial reports on the use of Ascorbic Acid (both for CMT 1A), the

highly successful work of high thoroughput screening of potential theraputic

targets for CMT treatment, the possibility of antibiotic use for CMT 2E, the

enlightened work of the private, venture capital funded Phase II human trials

project from the French biotech Pharnext, and the latest research from Italy on

the walking bioenergetics, neuromechanics and physical activity in persons with

Charcot-Marie-Tooth syndrome.

CMT research in total has made stellar strides since the first CMT subtype (CMT

1A) was defined in 1991. We've come a long way in 20 years!

World genetic research and two additional Italian studies, one looking at the

effect of recovery time after fatigue and another looking at the correlation

between levels of daily living activity and neuromuscular function fire us with

hope for the New Year 2011 and the possibility of treatment and total arrestment

of CMT once and for all.